• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Neuroimmunology of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis
Conclusion Recent advances in research on HTLV-1 provide better understanding of the molecular pathogenesis and mechanisms of HAM/TSP, and several clinical trials of novel therapies for patients with HAM/TSP have been initiated. However, long-term improvement of motor disability and quality of life still have not been achieved in HAM/TSP patients, and the clinical management remains challenging. Given that HAM/TSP is characterized by activated T-cells in both the periphery and CNS, studies in HAM/TSP will be highly informative for clarifying the pathogenesis of other neuroinflammatory disorders such as multiple sclerosis....
Source: Frontiers in Microbiology - April 23, 2019 Category: Microbiology Source Type: research

Giant-Cell Arteritis Presenting as Isolated Bilateral CN-VI Palsies: A Rare Case Report of a 65 Year Male. (P2.378)
Conclusions:GCA is the most prevalent systemic vasculitis in the elderly. It can present with a wide variety of symptoms ranging from fatigue, headache, visual loss, and even stroke. However as noted in this case, isolated CN-VI palsy can be a very rare, early manifestation of GCA. As GCA responds well to corticosteroid therapy, prompt diagnosis and treatment is critical to prevent and/or limit neurologic sequelae. As highlighted by this case, in the event of recurrent incidents and absence of other diagnosis; GCA should be considered even if headache is absent.Disclosure: Dr. Lunagariya has nothing to disclose. Dr. Patel ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Lunagariya, A., Patel, U., Kotadiya, F., Wilson, C. Tags: CNS Inflammatory Diseases and Differential Diagnosis II Source Type: research